Early Termination and Voluntary Withdrawal of Microbiome Immuno-Oncology Drug CJRB-101 Phase 1/2 Trial
Decision to early terminate and voluntarily withdraw the Phase 1/2 clinical trial of CJRB-101 (microbiome immuno-oncology drug) from US FDA and Korea MFDS
Reason: based on data, development progress, and business strategy review, not proceeding to Phase 2 and terminating early at current stage
Company plans to shift to new drug development and premium wellness business, strengthening profitability and cash flow-oriented structure
Humanitarian support and safety observation will be maintained for current trial participants
Decision date: 2026-05-12
KOSDAQ Filing Information
Filing: Major Management Matters Related to Investment Decision (Voluntary Withdrawal of Clinical Trial Plan, etc.)